Board and Executive Team

Robert Lilley
Chairman – BA (Yale)

40 years experience; SVP, Global Sales & Marketing for Digene Corp from IPO to acquisition by QIAGEN NV (in 2007) creating market & technology leader in molecular Dx. Then, Senior Advisor/Molecular Diagnostics for Developing World at QIAGEN. Consultant to John D Rockefeller 3rd Fund, 23andMe, ImpediMed Pty Ltd, Vertex Pharma, OpGen.

 

Rolland Carlson
Executive Director – BA, PhD

Over 25 years’ experience – business and new product development, global commercial and general management in biotechnology. President and CEO of WaferGen Biosystems; President and CEO of Asuragen Inc., a molecular diagnostic company. Vice President for Abbott Laboratories Inc., responsible for business development and licensing. Vice President and General Manager in Molecular Diagnostic Business for Vysis Inc. IVD market over the past 15 years.

 

Greg Brown
Non-Executive Director – BAppSc, MBA

35 years experience – medical devices and in-vitro-diagnostics. International roles for Baxter Diagnostics (Australia & UK), Senior Global Marketing Manager for Roche Molecular Systems, and VP Global Strategic Marketing for Digene Corp. Managing Director and CEO for ImpediMed Limited. Boards: StraxCorp, Minomic, UniQuest.

 

Laurie Hammond
Non-Executive Director – BSc, PhD

35 years experience. Start-up investor and Director. Chairman, Commercialisation Australia. Director inQbator, an early-stage venture fund. Director of, and investor in, several early stage Australian companies in IT and biotech sectors.

 

Tom Gibbs
Non-Executive Director – BSc, PhD

30 years experience in both start-ups and established companies in Europe and US, including Molecular Devices Corp, Covalys, Med Discovery, Debiopharm. Currently Director at Debiopharm Innovation Fund, Switzerland; responsible for diagnostic investments.

 

Tanja Dowe
Non-Executive Director – MSc

20 years experience – building business strategies, analyzing markets, strategy & transaction consulting, in- and out-licensing and business acquisitions. CEO of Debiopharm Innovation Fund SA. Managing Partner and Director at Innomedica Ltd., serves on the boards of GenePOC as the chair, Kaiku Health and formerly BC Platforms.

 

Katleen Verleysen
Non-Executive Director – MSc, PhD

15 years experience – medical devices and diagnostics. CEO of CellSeeQ, CEO, COO and Vice President of Operations and Technology at Pronota.  Founding scientists and Group Leader of Analytical Department at U.S.-based biotech company Serenex, acquired by Pfizer in 2008. Served on boards as chair of the Center for Medical Innovation and PharmaFluidics.